[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-mesenteric-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-mesenteric-ischemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,68,91,112,132,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639278","predictors-of-transmural-non-occlusive-mesenteric-ischemia-in-icu-patients-with-suspected-acute-mesenteric-ischemia-100639278",false,"NCT07610356","Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia","Mesenteric Ischemia in the ICU: A Prospective Observational Study Across Estonian Regional Hospitals","AMESI-EST","Inclusion criteria\n\n\\- Adult ICU patients in whom clinical suspicion of acute mesenteric ischemia is raised during their ICU stay.\n\nExclusion criteria\n\n* Patients who develop acute mesenteric ischemia outside of the intensive care unit,\n* Confirmed strangulating bowel obstruction,\n* Individuals younger than 18 years,\n* Chronic mesenteric ischemia without an acute event.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Acute mesenteric ischemia (AMI) is a rare but life-threatening condition associated with high mortality and major diagnostic challenges due to nonspecific clinical presentation and limited reliable biomarkers. Critically ill patients in the intensive care unit (ICU) are at particularly high risk of non-occlusive mesenteric ischemia (NOMI), a subtype of AMI characterized by impaired mesenteric perfusion without large-vessel occlusion. Despite advances in imaging, the diagnosis of NOMI remains difficult, and data specifically focusing on ICU patients with suspected AMI are limited.\n\nThis prospective observational multicenter study aims to identify independent predictors of transmural NOMI among ICU patients with suspected AMI. In addition, the study will describe demographics, comorbidities, clinical presentation, laboratory findings, diagnostic imaging, management strategies, and outcomes among ICU patients with NOMI, other forms of AMI, and patients with suspected but unconfirmed AMI. Consecutive adult ICU patients in whom clinical suspicion of AMI arises during ICU stay will be included across Estonian regional hospitals. The study is a local continuation of the international AMESI study, with a specific focus on critically ill ICU patients.",[25,26],"Non-Occlusive Mesenteric Ischaemia (NOMI)","Acute Mesenteric Ischemia",[28,29,30,31],"Acute mesenteric ischemia","non-occlusive mesenteric ischemia","transmural necrosis","predictors","RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":36},"2022-06-06",{"date":40,"type":21},"2026-09-05",{"name":42,"class":43},"University of Tartu","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100616249","assessment-of-quality-of-life-after-acute-mesenteric-ischemia-100616249","NCT07303153","Assessment of Quality of Life After Acute Mesenteric Ischemia","EQVIMA-1","Inclusion Criteria:\n\n* Adult patient (≥ 18 years)\n* Treated for mesenteric ischemia between 2010 and 2022 in the intensive care, cardiovascular, and digestive and vascular surgery departments of the Strasbourg University Hospitals\n\nExclusion Criteria:\n\n* Chronic mesenteric ischemia or other non-ischemic intestinal vascular pathologies such as mechanical causes.\n* Colonic ischemia",{"count":53,"type":21},100,"Acute mesenteric ischemia is a severe abdominal emergency associated with a poor prognosis. While numerous studies have been conducted on the incidence, outcomes, and risk factors of mesenteric ischemia, very few focus on the quality of life of patients.",[26],[26,57],"Quality of Life After Acute Mesenteric Ischemia","2025-12-11",{"date":60,"type":36},"2025-12-24",{"date":62,"type":36},"2024-10-24",{"date":64,"type":21},"2026-04",{"name":66,"class":43},"University Hospital, Strasbourg, France",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":67},"100325521","searching-biomarkers-of-acute-intestinal-ischemic-injuries-100325521","NCT03518099","Searching Biomarkers of Acute Intestinal Ischemic Injuries","Survibio","Inclusion Criteria:\n\n* age\\> 18 years\n* Acute abdominal pain requiring an injected abdominal injected CT scan, at best at non-injected \u002F early arterial \u002F portal time\n* Admitted or attended in Beaujon and \u002F or Bichat hospitals\n* Patient covered by a social security scheme\n* Written consent\n\nExclusion Criteria:\n\n• lack of abdominal CT scan",{"count":76,"type":21},556,"INTERVENTIONAL",[79],"NA","The aim of the SURVIBIO study is to characterize accurate biomarkers for acute mesenteric ischemia, in particular at early stages.\n\nIn the study, the development of biomarkers will be based on the analysis of human biological samples from patients and controls that will be conserved in a biological library. Samples will be analysed in the Laboratory for Vascular Translational Sciences (LVTS, Inserm U1148), in the Department of Biochemistry (Pr Puy, Dr Peoc'h), in Paris V university , in Imperial College of London (Pr Dumas), in Jacques Monod Institute and in Maastricht University Medical Center . The candidate markers will be determined according to an a priori method (form markers already described in the literature) and with no a priori strategy using -omics methods.",[26],"2025-12-08",{"date":84,"type":36},"2025-12-16",{"date":86,"type":36},"2018-11-16",{"date":88,"type":21},"2028-07-30",{"name":90,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":77,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":67},"100582918","evaluation-of-the-discriminative-abilities-of-biomarkers-for-the-diagnosis-of-acute-mesenteric-ischemia-compared-with-another-similar-clinical-presentation-a-pilot-study-100582918","NCT06869564","Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study","SOS-ISMES","Inclusion Criteria:\n\n* Male or female, 18 years of age or older\n* with an indication (hyperintense abdominal pain with no obvious diagnosis other than acute mesenteric ischemia) for an injected abdominopelvic scan for hyperintense abdominal pain suspected of acute mesenteric ischemia\n* Including pregnant or breast-feeding women, as this is a risk factor for AMI in young subjects\n* Affiliated with the French social security system\n* Able to express non-opposition in writing\n\nExclusion Criteria:\n\n* Presenting acute myocardial ischemia, to avoid biasing the levels of the biomarkers studied (increased in this clinical situation)\n* Patient in a period of exclusion from another research protocol at the time the non-opposition is signed,\n* Person protected by articles L1121-6 and L1121-8 of the French Public Health Code (deprived of liberty by court order, socially vulnerable, adult incapable or unable to express non-opposition).\n* Persons who are unable to read and understand the French language sufficiently to give their consent to participate in research.",{"count":99,"type":21},130,[79],"Acute mesenteric ischemia (AMI) is associated with high mortality (50-80%). The prognosis depends on the time it takes to diagnose the condition, and the possibility of revascularization in eligible patients. Delayed diagnosis is due in particular to the aspecific clinical presentation and the absence of biomarkers to guide early diagnosis, lactates often being elevated at an already irreversible stage. Adenosine deaminase is produced in the presence of ischemia (known from myocardial ischemia), and is present on the surface of intestinal villi. The investigator's hypothesis is that, in the event of digestive ischemia resulting in abnormalities of mesenteric permeability, adenosine deaminase will enter the bloodstream and increase its soluble plasma activity, along with an increase in lymphocyte-bound adenosine deaminase.\n\nThe main objective is to evaluate the discriminatory capacities of soluble adenosine deaminase, collected via blood sampling, for the diagnosis of IMA in comparison with the reference method (injected abdominopelvic CT scan), performed for abdominal pain suggestive of IMA.\n\nThe study will be based on a prospective monocentric cohort. Currently, there is no specific biological marker for IMA, and the gold standard for diagnosis is the injected abdominopelvic CT scan, performed for hyperintense abdominal pain.\n\nTwo groups will be identified on the basis of the gold-standard abdominopelvic scan:\n\n* the \"IMA patients\" group: patients with hyperintense abdominal pain, and IMA confirmed by CT scan\n* the \"non-IMA patients\" group: patients with hyperintense abdominal pain, but with a diagnosis other than IMA on the CT scan.\n\n  130 subjects will be included in this study Inclusion period: 18 months Follow-up period: 1 month Analysis period: 5 months Total duration: 24 months",[26],"2025-08-21",{"date":105,"type":36},"2025-08-28",{"date":107,"type":36},"2025-06-29",{"date":109,"type":21},"2027-02-01",{"name":111,"class":43},"Assistance Publique Hopitaux De Marseille",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":22,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":67},"100550329","the-feasibility-of-a-radiological-score-based-on-ct-signs-for-recognizing-salvageable-bowel-in-acute-mesenteric-ischemia-100550329","NCT06445660","The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia","The Feasibility of a Radiological Score Based on Quantified Analysis of Computed Tomography Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia: A Retrospective Analysis of Prospective Study","AMESIradiol","Inclusion Criteria:\n\n* Participant in AMESI study\n* confirmed or suspected acute mesenteric ischaemia\n* CT scan of the entire abdominal cavity \u002F full body using intravenous contrast media is available\n\nExclusion Criteria:\n\n* Scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.",{"count":121,"type":21},200,"1 Year","Computed tomography (CT) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (AMI). CT imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. This moment is pivotal in selecting the treatment strategy for AMI - in the absence of irreversible damage; reperfusion therapy can preserve intestinal viability, thereby avoiding the need for bowel resection. The present study tests the hypothesis that combining several symptoms may enhance the diagnostic performance of CT scanning in detecting salvageable bowel in patients with AMI. This study is an ancillary component of the AMESI study (Clinical Trials: NCT05218863) - a prospective, multicentre observational study aimed at identifying the incidence and describing the outcomes of acute mesenteric ischemia (AMI) in adult hospitalized patients. The ultimate purpose of the present study is to create a computed tomography-based radiological score for the assessment of bowel viability in patients with AMI.",[26],"2025-03-24",{"date":127,"type":36},"2025-03-25",{"date":38,"type":36},{"date":130,"type":21},"2025-05-31",{"name":42,"class":43},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":77,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100545840","phase-3-oral-antibiotics-in-acute-mesenteric-ischemia-100545840","NCT06387147","ORal Antibiotics in Acute Mesenteric Ischemia","ORal Antibiotics in Acute Mesenteric Ischemia: a Multicenter Randomized Controlled Trial","ORIAMI","Inclusion Criteria:\n\n* Adult patient aged 18 and less 90\n* AMI of arterial occlusive origin, defined by the combination of\n\n  1. Onset \\\u003C 7 days of clinical, biological and\u002For radiological signs of acute intestinal injury in the territory of at least superior mesenteric ischemia, including right-side colitis,\n  2. significant vascular obstruction \\> 75% of the superior mesenteric artery, and\n  3. no alternative diagnosis\n* Admitted to the SURVI care network (Beaujon Hospital intensive care unit or SURVI, Bichat intensive care unit or vascular surgery department)\n\nExclusion Criteria:\n\n* Other forms of mesenteric ischemia (chronic without acute manifestations, venous, non-occlusive, strangulation, aortic dissection)\n* Isolated left-side ischemic colitis\n* Mesenteric vascular lesion without small bowel injury or right colon\n* Not eligible for vascular or digestive surgery or intensive care (palliative context)\n* Indication for an emergency surgical intestinal resection at the admission to the SURVI care network\n* Indication for urgent systemic antibiotic treatment on admission (evidence of sepsis defined as a SOFA score of 2 or more associated with an infection)\n* Systemic or oral antibiotic therapy within 7 days before inclusion\n* Known hypersensitivity to the active substance \u002Fexcipients\n* Contraindications to the investigational medicinal products (gentamicin, metronidazole)\n* Unable to give consent (under guardianship or curatorship)\n* Subject deprived of freedom, subject under a legal protective measure\n* Patient refusal to participate\n* Non-affiliation to a social security regimen or CMU\n* Patient under State Medical Aid\n* Pregnant or breastfeeding women\n* Participation in another clinical study involving investigational medicinal product or patient being in the exclusion period at the end of a previous study","90 Years",{"count":142,"type":21},196,[144],"PHASE3","Acute mesenteric ischemia (AMI) is a life-threatening condition with an increasing incidence (7-13\u002F100000 PY). The mortality of AMI is associated with the development and extent of transmural intestinal necrosis (IN), ranging from 25% without IN to 75% with IN. Given its potential reversibility, preventing the progression of AMI towards IN is now considered a primary therapeutic goal. Early management of AMI can thus avoid fatal outcomes and prevent lifelong complications such as short bowel syndrome. Following the results of a pilot study showing an improvement in survival and lower resection rates, our team created a first-of-its-kind intestinal stroke center (SURVI unit, Beaujon Hospital, Clichy, France) that provides 24\u002F7 standardized multimodal and multidisciplinary care to AMI patients referred from all hospitals in the Paris region. As no randomized clinical trial has ever been conducted, the treatment offered by SURVI is based on pathophysiological knowledge and observational clinical data. AMI naturally progresses to sepsis, surgical complications, and multi-organ failure, direct consequences of IN. Features of sepsis are reported in up to 90% of AMI patients compared with 3-22% of patients with brain or myocardial ischemia, supporting a specific septic component in AMI. Experimental studies demonstrated reduced translocation and mortality in germ-free animals or after administration of oral antibiotics targeting Gram-negative and anaerobic early bacterial overgrowth and translocation. In a prospective observational study, the investigators recently suggested a protective effect of systematic oral antibiotics in terms of intestinal preservation, yielding a reduced occurrence of IN (HR: 0.16, 95% confidence interval 0.03-0.62). However, the systematic use of oral antibiotics in AMI remains controversial due to the individual and collective risk of increasing the carriage of multi-drug resistant bacterias.",[26],[148],"necrosis","2025-02-17",{"date":151,"type":36},"2025-02-19",{"date":153,"type":36},"2025-01-31",{"date":155,"type":21},"2027-11-01",{"name":90,"class":43},4,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":77,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":44},"100532447","biomarkers-in-prediction-of-ami-100532447","NCT06212921","Biomarkers in Prediction of AMI","Biomarkers In Prediction of Acute Mesenteric Ischaemia: a Prospective Multicentre Study (BIPAMI Study)","BIPAMI","Inclusion Criteria:\n\n* Age 18 years or older\n* Initial decision in favour of further diagnostics of mesenteric ischaemia\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Consent declined by patient or next of kin (delayed consent)\n* Chronic mesenteric ischaemia without an acute event\n* Immediate decision for withdrawal of further diagnostics and active treatment\n* Referral from another hospital with already established diagnosis of AMI\n* AMI diagnosed at surgery without previously having been considered",{"count":167,"type":21},250,[79],"Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.",[26],"2024-11-27",{"date":173,"type":36},"2024-12-03",{"date":175,"type":36},"2024-10-14",{"date":177,"type":21},"2025-12",{"name":42,"class":43}]